Free Trial

Virax Biolabs Group (VRAX) Competitors

Virax Biolabs Group logo
$0.86 +0.01 (+0.59%)
As of 07/3/2025 01:43 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

VRAX vs. SNSE, XFOR, SNPX, CSCI, PHXM, BCDA, NLSP, GLYC, LSB, and ADXN

Should you be buying Virax Biolabs Group stock or one of its competitors? The main competitors of Virax Biolabs Group include Sensei Biotherapeutics (SNSE), X4 Pharmaceuticals (XFOR), Synaptogenix (SNPX), COSCIENS Biopharma (CSCI), PHAXIAM Therapeutics (PHXM), BioCardia (BCDA), NLS Pharmaceutics (NLSP), GlycoMimetics (GLYC), LakeShore Biopharma (LSB), and Addex Therapeutics (ADXN). These companies are all part of the "pharmaceutical products" industry.

Virax Biolabs Group vs. Its Competitors

Sensei Biotherapeutics (NASDAQ:SNSE) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

In the previous week, Sensei Biotherapeutics' average media sentiment score of 0.00 equaled Virax Biolabs Group'saverage media sentiment score.

Company Overall Sentiment
Sensei Biotherapeutics Neutral
Virax Biolabs Group Neutral

Virax Biolabs Group's return on equity of 0.00% beat Sensei Biotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Sensei BiotherapeuticsN/A -66.72% -57.10%
Virax Biolabs Group N/A N/A N/A

Sensei Biotherapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500. Comparatively, Virax Biolabs Group has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500.

Sensei Biotherapeutics currently has a consensus price target of $90.00, indicating a potential upside of 891.74%. Virax Biolabs Group has a consensus price target of $3.00, indicating a potential upside of 246.82%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Sensei Biotherapeutics is more favorable than Virax Biolabs Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sensei Biotherapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.33
Virax Biolabs Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

10.5% of Sensei Biotherapeutics shares are owned by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are owned by institutional investors. 23.2% of Sensei Biotherapeutics shares are owned by insiders. Comparatively, 45.1% of Virax Biolabs Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Virax Biolabs Group has higher revenue and earnings than Sensei Biotherapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sensei BiotherapeuticsN/AN/A-$30.16M-$23.00-0.39
Virax Biolabs Group$10K375.41-$6.06MN/AN/A

Summary

Virax Biolabs Group beats Sensei Biotherapeutics on 6 of the 11 factors compared between the two stocks.

Get Virax Biolabs Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRAX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRAX vs. The Competition

MetricVirax Biolabs GroupMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.69M$2.92B$5.56B$9.05B
Dividend YieldN/A2.44%5.24%3.99%
P/E RatioN/A21.5627.6520.23
Price / Sales375.41283.26419.56119.26
Price / CashN/A41.7026.2128.59
Price / Book0.697.538.035.65
Net Income-$6.06M-$55.14M$3.18B$249.15M
7 Day Performance10.90%4.61%2.93%3.28%
1 Month Performance-11.60%0.90%1.72%3.95%
1 Year Performance-29.10%5.40%34.39%20.98%

Virax Biolabs Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRAX
Virax Biolabs Group
2.854 of 5 stars
$0.87
+0.6%
$3.00
+246.8%
-29.1%$3.69M$10K0.005
SNSE
Sensei Biotherapeutics
4.1881 of 5 stars
$8.75
+2.0%
$90.00
+928.6%
-27.1%$11.03MN/A-0.3840Gap Down
XFOR
X4 Pharmaceuticals
4.3383 of 5 stars
$1.90
-0.3%
$72.33
+3,717.1%
-88.1%$10.97M$2.56M0.8880News Coverage
SNPX
Synaptogenix
1.1488 of 5 stars
$7.85
+29.8%
$14.00
+78.3%
+106.8%$10.91MN/A-0.784Gap Down
High Trading Volume
CSCI
COSCIENS Biopharma
N/A$3.42
+0.6%
N/AN/A$10.77M$9.59M-0.5920
PHXM
PHAXIAM Therapeutics
N/A$3.10
flat
N/AN/A$10.58M$32.66M0.0049
BCDA
BioCardia
3.9871 of 5 stars
$2.04
+4.4%
$25.00
+1,128.5%
-29.0%$10.54M$60K-0.8740News Coverage
Positive News
Insider Trade
NLSP
NLS Pharmaceutics
N/A$2.88
-0.7%
N/A+1,191.0%$10.37MN/A0.006News Coverage
Analyst Upgrade
Gap Up
GLYC
GlycoMimetics
1.1469 of 5 stars
$0.16
-6.6%
N/A-99.4%$10.00M$10K-0.3450High Trading Volume
LSB
LakeShore Biopharma
0.3358 of 5 stars
$1.06
+3.4%
N/AN/A$9.82M$80.82M0.00773Positive News
Gap Up
ADXN
Addex Therapeutics
2.701 of 5 stars
$9.21
-2.2%
$30.00
+225.9%
+7.0%$9.76M$460K-27.0730High Trading Volume

Related Companies and Tools


This page (NASDAQ:VRAX) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners